A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Launched by BIOGEN · Apr 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medicine called felzartamab to see how it affects adults with a kidney condition known as immunoglobulin A nephropathy (IgAN). Specifically, the researchers want to find out if felzartamab can help reduce the amount of protein in the urine, which indicates how well the kidneys are functioning. Participants in this study will receive either felzartamab or a placebo (a treatment that looks like the real medicine but has no active ingredients) through an IV infusion over 24 weeks. After that, there will be an additional follow-up period lasting 80 weeks. Overall, participants will be involved in the study for about two years and will have 17 visits during this time.

To join the study, participants need to be adults aged 18 and older who have been diagnosed with IgAN within the last 10 years and have a certain level of kidney function. They should also have a specific amount of protein in their urine. However, there are some conditions that could prevent someone from participating, such as having other serious kidney diseases or infections. It's important for potential participants to discuss their medical history with the study team to see if they qualify. This trial is not yet recruiting, but it aims to gather valuable information on the safety and effects of felzartamab for people with this kidney condition.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Biopsy-confirmed diagnosis of IgAN within the past 10 years prior to signature of the informed consent form (ICF). For participants with diabetes mellitus type 2, biopsy confirmation of IgAN diagnosis must be done within the past 24 months prior to signing the ICF.
• • An eGFR ≥ 30 mL/min/1.73m\^2 at Screening as calculated using the 2021 chronic kidney disease epidemiology (CKD-EPI) creatinine formula. An eGFR of ≥ 20 and \< 30 mL/min/1.73m\^2 is acceptable for the cohorts 3 and 4.
• • Proteinuria of ≥ 1.0 gram per day (g/day) or UPCR ≥0.8 gram per gram (g/g) as assessed by an adequate 24-hour urine collection.
• • Clinically stable on a maximally tolerated dose or maximally approved dose of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) for at least 12 weeks prior to Screening, or intolerant of ACEI or ARB. If intolerant, this must be discussed with the Medical Monitor prior to randomization. Participants may also be using sodium-glucose cotransporter-2 inhibitors (SGLT2is), endothelin receptor antagonists (ERAs) approved for the treatment of IgAN, and/or mineralocorticoid receptor antagonists (MRAs) as long as the dose is stable for at least 12 weeks prior to Screening. Participants should remain on stable doses of these background medications for the duration of the study. Once the ICF is signed and thereafter, the doses cannot be changed during the study nor the drugs discontinued except if deemed related to an AE. Participants using sparsentan will not be permitted to use simultaneous ACEI or ARB medication.
• Key Exclusion Criteria:
• • Secondary forms of IgAN, indicated by the presence of any other systemic disease potentially leading to IgA deposits as determined by the Investigator.
• • History of rapidly progressive variant of IgAN, defined as eGFR loss by \> 50% per 3 months and not explained by changes in renin-angiotensin system (RAS) blockade or other factors.
• • Nephrotic syndrome presumed to be due to minimal change disease (MCD) variant.
• • Concomitant other progressive glomerulonephritis or non-immunologic glomerular disease such as diabetic nephropathy.
• • Type 2 diabetes mellitus with Hemoglobin A1c (HbA1c) \> 8% at Screening, or evidence of diabetic nephropathy on biopsy, history of diabetic microvascular or macrovascular disease (eg, diabetic retinopathy, peripheral neuropathy).
• • Any diagnosed or suspected immunosuppressed or immunodeficient state such as asplenia, human immunodeficiency virus (HIV), primary immunodeficiencies, organ or bone marrow transplantation, with the exception of corneal transplants.
• • Previously treated with immunosuppressive or other immunomodulatory agents such as but not limited to cyclophosphamide, rituximab, infliximab, eculizumab, canakinumab, mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), cyclosporine, tacrolimus, sirolimus, everolimus, or systemic corticosteroids exposure (\> 7.5 milligrams per deciliter \[mg/d\] prednisone/prednisolone equivalent) within 4 months (or 12 months for rituximab) prior to Screening.
• • Participants currently treated with oral budesonide. Participants who have stopped this therapy ≥ 4 months prior to Screening may be eligible.
• • Active clinically significant infections, known history of recurrent clinically significant infection, or Screening laboratory evidence consistent with an active infection, or IV anti-infectives (antibacterials, antiviral or antifungals). Participants with a history of opportunistic infections are excluded.
• • Hypogammaglobulinemia: Serum Immunoglobin G (IgG) \< 6.0 gram per litre (g/L), at Screening.
• • Note: Other protocol-defined Inclusion/Exclusion criteria may apply.